CA-BOEHRINGER-INGELHEIM
Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences’ best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim’s two-pronged research strategy combining cancer cell-directed and immune cell-targeting compounds, further strengthening the company’s pipeline.
Cancer immunotherapies have brought dramatic breakthroughs, but only for a minority of cancer patients. 3T‘s platform aims to address this challenge by identifying novel shared T-cell receptor (TCR) targets of productive immune responses and comprehensively screening TCRs and TCR mimetics for specificity and off-target cross-reactivities. The platform identifies the most prevalent and immunogenic targets in solid tumors by uniquely combining high-diversity target libraries with active machine learning. This may lead to tumor-specific, safer therapies that can be delivered at higher doses.
“At Boehringer Ingelheim, we are committed to transforming patients’ lives. Through our new partnership with 3T Biosciences, we aim at accelerating and expanding our pipeline of first-in-class T-cell based therapies for patients affected by cancer,” said Lamine Mbow, Ph.D., Global Head of Cancer Immunology + Immune Modulation, Boehringer Ingelheim.
“On behalf of the entire team at 3T Biosciences, we are extremely pleased to partner with Boehringer Ingelheim, a company advancing transformative cancer treatments,” said Stefan J. Scherer, M.D., Ph.D., president and CEO of 3T Biosciences. “3T’s 3T-TRACE discovery platform has the potential to transform the treatment of cancers and beyond. By using data from patients for patients we aim to discover the best immunogenic targets for multiple tumor indications and across patient populations.”
Under the agreement, Boehringer Ingelheim will provide patient-derived TCR data to fuel 3T’s target discovery efforts to identify antigens using its 3T TRACE discovery platform. 3T will receive an upfront payment and research and development support, and is eligible for discovery, preclinical, clinical, regulatory, and commercial milestones totaling $268 million in addition to royalties on future Boehringer Ingelheim product sales. Boehringer Ingelheim is eligible to receive royalties on future product sales by 3T Biosciences arising from the agreement.
For the full press release and link to “Notes to Editors” please click here:
Press Release
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005420/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tigo Energy Resolves Multi-Year Patent Infringement Litigation With SMA13.5.2025 15:00:00 CEST | Press release
Settlement validates Tigo Intellectual Property, concludes IP litigation with SMA, and reinforces innovation in the marketplace. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that it has reached a multi-year settlement with SMA (SMA Solar Technology AG and SMA Solar Technology America LLC) over litigation regarding the infringement of Tigo intellectual property by SMA. The settlement concludes the infringement complaint brought by Tigo on July 11, 2022, Case No. 1:22-cv-00915 (D. Del.) alleging infringement of certain patents by SMA. Terms of the settlement will remain undisclosed. According to National Electric Code § 690.12, “Rapid Shutdown of PV Systems on Buildings” requires that PV system circuits “installed on or in buildings shall include a rapid shutdown function to reduce shock hazard for emergency responders.” Tigo rapid shutdown technology is compliant with UL 1741, the Standard
GPs Rethink Operational Tactics Amid Rising SPV Complexity13.5.2025 15:00:00 CEST | Press release
Nearly three quarters of GPs cite growing regulatory burdens as a top risk LP demand accelerates shift to co-investment, sector-specific, and evergreen structures63% of GPs scale outsourcing to enhance efficiency and drive growth Faced with rising regulatory demands and operational pressures, general partners (GPs) are increasingly turning to outsourcing and technology to manage special purpose vehicles (SPVs) more efficiently. This trend is highlighted in a new report from CSC, the leading provider of global business administration and compliance solutions. CSC surveyed 400 GPs across the Americas, Europe (including the U.K.), and Asia Pacific to uncover how today’s market shifts and operational pressures are reshaping SPV management strategies.1 The full findings are detailed in the report SPV Global Outlook 2025: How GPs are Shaping Strategies for Long-Term Success. Regulatory compliance and risk mitigation are firmly at the top of GPs’ agendas, with nearly three-quarters identifyin
Boomi Announces FY25 EMEA Partner Award Winners13.5.2025 15:00:00 CEST | Press release
Boomi™, the leader in AI-driven automation, announced today the winners of its FY25 Europe, Middle East, and Africa (EMEA) Partner Awards - recognized at the 2025 Boomi Partner Summit held in Dallas, Texas. The awards recognize innovative partner organizations across the region that have harnessed the power of the Boomi Enterprise Platform to deliver outstanding customer outcomes, accelerate digital transformation, and build scalable, AI-ready data ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513864198/en/ Boomi Announces FY25 EMEA Partner Award Winners Award winners were selected based on their ability to creatively solve complex business challenges, deliver measurable impact, and champion sustainable, forward-looking solutions for customers leveraging the Boomi platform’s end-to-end capabilities. “Across EMEA, organizations are under immense pressure to automate, integrate, and innovate — all while prepari
1GLOBAL Enables N26 to Become Germany’s first Digital Bank to offer eSIM Mobile Plans13.5.2025 14:30:00 CEST | Press release
In a move set to reshape the intersection of fintech and telecom, 1GLOBAL, a technology-driven global mobile communications provider, has teamed up with N26 to enable it to become the first digital bank in Germany to offer local mobile plans. This partnership will grant N26’s German customers seamless access to flexible, affordable, and contract-free mobile connectivity—all activated directly through the N26 app. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513954446/en/ 1GLOBAL, a technology-driven global mobile communications provider, has teamed up with N26 to enable it to become the first digital bank in Germany to offer local mobile plans. By integrating 1GLOBAL’s cutting-edge API, N26 has unlocked a frictionless mobile experience that eliminates the need for physical SIM cards, lengthy contracts, or cumbersome paperwork. Customers can activate their mobile plans in a few taps, enjoying instant connectivity that mi
Novotech Wins Citeline CRO Partnership of the Year Award for Strategic Collaboration with Tune Therapeutics13.5.2025 14:05:00 CEST | Press release
Novotech a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is proud to announce it has been awarded the Citeline CRO Partnership of the Year Award in recognition of its collaboration with Tune Therapeutics, a pioneering epigenetic editing company. This honor celebrates the teams’ partnership and sets a benchmark for CRO–biotech partnerships. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513574699/en/ Novotech is proud to announce it has been awarded the Citeline CRO Partnership of the Year Award in recognition of its collaboration with Tune Therapeutics. The CRO Partnership of the Year award honors outstanding collaboration between a CRO and a pharmaceutical or biotech company that has advanced clinical programs through strong alignment and shared goals. Sarah Anderson, Director of Therapeutic Strategy, and Steve Roan, Associate Director of Business Development, acce
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom